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Summary
Objective: Evaluation of the effect of a ginger extract (Zintona EC) on patients suffering from gonarthritis.
Material and methods: Twenty-nine patients (6 men and 23 women) with symptomatic gonarthritis (ACR criteria), in the age range 42–85
years, were included after randomization in a double blind, placebo controlled, crossover study of 6 months’ duration. The treatment group
was given a ginger extract (250 mg of Zingiberis Rhizoma per capsule, qid), while the placebo group received the same number of identical
looking capsules per day. The crossover occurred after 3 months of therapy. Results were evaluated by a 100 mm visual analog scale (VAS)
of pain on movement and of handicap.
Results: Eight patients dropped out because of inefficacy, three from group 1 (ginger extract first) and five from group 2 (placebo first). One
patient from group 1 and one from group 2 dropped out because of heartburn (while they were on ginger extract). Twenty patients completed
the study period of 24 weeks and 19 that of 48 weeks follow-up. By the end of 24 weeks there was a highly statistically significant difference
between the VAS of pain and handicap of the two groups (P<0.001). However, at crossover both groups showed a statistically significant
decrease in VAS of pain on movement and of handicap, but the differences between the groups did not reach statistical significance.
Conclusions: Zintona EC was as effective as placebo during the first 3 months of the study, but at the end of 6 months, 3 months after
crossover, the ginger extract group showed a significant superiority over the placebo group.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is the most common rheumatic disease,
the prevalence of which increases with advancing age1,2.
The 1995 American College of Rheumatology (ACR) rec-
ommendations for the management of OA of the hip and
knee outlined both the use of nonpharmacological modali-
ties as well as that of pharmacological agents3. The 2000
ACR update of these recommendations4,5 includes a dis-
cussion of the place of acetaminophen, COX-2 inhibitors
and nonselective NSAIDs, tramadol, opioids, intra-articular
glucocorticoids and hyaluronan, topical capsaicin and
methylsalicylate in OA management. Agents under investi-
gation, such as glucosamine, chondroitin sulfate and
others, are also discussed. Altman and Marcussen6 re-
cently reported a statistically significant effect of a ginger
extract on reduction of knee pain in patients with OA. Their
study was a 6-week double blind placebo controlled
parallel-group study.
We report here the effects of a ginger extract on symp-
tomatic OA of the knee in a double blind placebo controlled,
crossover study of 6 months’ duration.
Patients and methods
STUDY DESIGN
Twenty-nine patients (six men and 23 women) aged
42–85 years were included in the study after they signed an
informed consent according to the Ethics Committee
requirement.
INCLUSION CRITERIA
Patients aged 40–85 years of both genders, with a
diagnosis of OA of the knee according to the ACR criteria7
(showing at least one osteophyte on X-ray) and corre-
sponding to OA grades 2, 3 or 4 by the Kellgren and
Lawrence criteria8, were considered for inclusion. They had
to report pain on knee movement on a 100 mm visual
analog scale (VAS) of at least 35 mm (VA≥35 mm) after a 4
day washout period of any previous medication. Patients
were excluded from the trial if pregnant or lactating or not
using acceptable contraception, if they had participated in
any other drug trial during the preceding 3 months, if they
had intra-articular injections of corticosteroids or hyaluro-
nan within the preceding 3 months, if they were on
glucosamine/chondroitin preparations or diacerein less
than a month before the trial onset, if they were on
anticoagulants except for mini-aspirin (75–325 mg/day), if
they had, besides OA, a concomitant rheumatic disease or
secondary OA, or recent surgical orthopedic intervention in
the lower limbs (within 6 months prior to trial onset). They
were also excluded if mentally incapable of understanding
or complying with the study protocol or for failing to sign the
informed consent.
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No active physiotherapy or balneotherapy for the knees
was allowed during the trial period.
After randomization by computer-generated allocation
schedule they were divided into two groups: group 1 (14
patients, who received the ginger extract first) and group 2
(15 patients who received placebo first). Both patients and
investigators were blinded to treatment assignment. After
12 weeks, group 1 was switched to placebo and group 2
was given ginger extract for an additional 12 weeks. By
the end of the double blind trial at week 24 the code
was broken and interested study participants continued
on ginger extract and were followed for an additional
24 weeks.
Demographic characteristics of patients included in the
study and radiographic classification of the target knee are
described in Table I.
TREATMENT
Following discontinuation of any NSAID treatment for 4
days (washout period) patients were allocated to either
Zintona EC (enteric coated) or placebo which were admin-
istered qid in identical opaque capsules. Paracetamol, up
to four tablets per day, was allowed throughout the study
except for a 12 h period before every point of clinical
evaluation (weeks 4, 12, 16, 24, 32, 40 and 48) and their
consumption recorded. The preparation Zintona EC (en-
teric coated ginger extract) was produced by Dalidar
Pharma (Beer Sheva). It is a preparation (250 mg per
enteric coated capsule) based on an extract of the plant
ginger (Zingiber officinale). The plant root was subjected to
extraction by liquid carbon dioxide under supercritical con-
ditions. The liquid extract was absorbed on maltodextrin
and microencapsulated to form an enteric coated product.
The potency of the preparation was followed by analysis
with HPLC on the active molecule gingerol. The dissolution
of the preparation was done in a USP type 2 dissolution
apparatus in gastric fluid (0.1 M HCl) for 1 h and the pH
was rapidly increased to that of intestinal fluid (phosphate
buffer pH7.4). The release of gingerol was followed at
several time points by HPLC analysis. The preparation was
designed to release 20% under acidic gastric conditions in
2 h and the rest of the active material under intestinal
conditions. Each capsule was filled to contain 10 mg gin-
gerol. Placebo capsules contained maltodextrin only.
ASSESSMENTS AND STATISTICAL ANALYSIS
VAS of pain and handicap were determined by the
Hebrew validated version of WOMAC9. Knee circumfer-
ence was measured by tape at the level of the patellar
center. Means of VAS of pain on movement, handicap and
target knee circumference were calculated at each visit
while stratifying for treatment group. The means of each of
these visits were compared to the baseline mean (the
second visit, after 4 days of washout). Statistical signifi-
cance of these comparisons was calculated by the paired
t-test. At each visit the differences from baseline of the
means of VAS of pain on movement, handicap and target
knee circumference were compared between the treatment
groups. The statistical significance of these comparisons
was calculated by independent sample t-test.
Data concerning pain on movement, handicap and knee
circumference reduction were analyzed by intention to
treat. Since we could not compare means because the
results concerning those who were lost to follow-up were
not available, the intention to treat analysis was done for
success versus failure, while referring to those who were
lost to follow-up as treatment failures. Patients who re-
ported more than 30% reduction in pain and handicap or
presented more than 5% reduction in knee circumference
were regarded as treatment success. The proportion of
treatment success was calculated at each visit, while those
who were lost to follow-up were regarded as treatment
failure. These proportions were compared between treat-
ment groups. Statistical significance was calculated by
Fisher’s exact test.
Results
The means of VAS of pain on movement and handicap at
each visit, according to treatment group, are presented in
Figs. 1 and 2 and Table II. During the first 12 weeks of the
trial (phase one), VAS of pain on movement and VAS of
handicap were reduced in both treatment groups. By the
12th week, in those treated with Zintona EC, the mean VAS
of pain on movement was reduced from 76.14 (95% CI:
67.69–84.60) at baseline to 41.00 (95% CI: 22.50–59.49)
(P0.001) and that of handicap was reduced from 75.86
(95% CI: 68.00–83.72) at baseline to 39.72 (95% CI:
22.24–57.22) (P0.001). In those who were treated with
placebo, the mean VAS of pain on movement decreased
from 76.87 (95% CI: 71.64–82.09) at baseline to 50.00
(95% CI: 33.46–66.53) (P0.001) and that of handicap
decreased from 73.47 (95% CI: 66.66–80.28) to 46.08
(95% CI: 29.75–62.40) (P0.002). The differences be-
tween groups were not statistically significant. At phase two
(after crossover) VAS of pain on movement and of handi-
cap continued to decrease in the group that switched from
placebo to Zintona EC, with means of 9.30 (95% CI:
3.29–15.31) and 10.00 (95% CI: 3.84–16.16), respectively,
at the 24th week. In the groups that switched from Zintona
EC to placebo, these means started rising, with the mean
VAS of pain on movement and of handicap reaching 82.10
(95% CI: 69.81–94.39) and 80.80 (95% CI: 68.47–93.12),
respectively, at the 24th week. The differences at this time
were found to be statistically significant (P<0.001 for both
comparisons). At phase three, when patients from both
groups received Zintona EC, VAS of pain on movement
and of handicap remained low in the group that continued
Zintona EC from phase two, and decreased again in the
group that received placebo at phase two. Both groups
reached a low mean, which was statistically different from
the baseline mean. No statistically significant difference
was observed between the groups at this phase.
Table I
Demographic characteristics of patients and radiographic
classification of knee OA
Group 1
(ginger first)
Group 2
(placebo first)
Age: mean (range, years) 64.7 (47–85) 59.3 (42–81)
Sex: male/female ratio 1/13 5/10
Disease (OA) duration:
mean years±SD
8±4.8 5.9±3.4
Radiographic classification
of knee OA
Stage 2 3 2
Stage 3 7 10
Stage 4 4 3
784 I. Wigler et al.: Ginger extract effect on gonarthritis
At phase one, knee circumference was reduced in both
treatment groups (Fig. 3). In those who were treated with
Zintona EC, the mean target knee circumference de-
creased from 43.25 cm (95% CI: 40.37–46.13) at baseline
to 39.36 cm (95% CI: 36.77–41.95) at the 12th week (P
0.003), while in those who were treated with placebo, it
decreased from 41.27 cm (95% CI: 39.52–43.01) to
38.58 cm (95% CI: 36.71–40.45) at the 12th week (P<
0.001). However, reduction of knee circumference in the
group treated with Zintona EC was greater, though the
difference was not statistically significant (P0.15). At
phase two (after crossover), the target knee circumference
stopped decreasing and even increased in the group that
moved from Zintona EC to placebo, while it continued to
decrease in the group that moved from placebo to Zintona
EC. At phase three, when both groups received Zintona
EC, the mean target knee circumference continued to
decrease in both groups. Groups 1 and 2 reached a low
Fig. 1. Comparison of mean VAS of pain on movement in the two treatment groups.
Fig. 2. Comparison of mean VAS of handicap in the two treatment groups.
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Table II
Mean VAS of pain on movement and handicap at each visit, according to treatment group
Time N Mean VAS of pain on movement Mean VAS of handicap
Group 1* Group 2* Group 1* Group 2* Group 1* Group 2*
Mean P-value† Mean P-value† P-value‡ Mean P-value† Mean P-value† P-value‡
−4 days 14 15 70.43 – 76.00 – 0.233 70.21 – 72.13 – 0.691
0 (baseline) 14 15 76.14 – 76.87 – 0.875 75.86 – 73.47 – 0.623
2 weeks 13 15 63.23 0.017 64.27 0.038 0.895 61.15 0.010 62.53 0.087 0.862
4 weeks 12 15 47.17 <0.001 54.33 0.005 0.411 47.58 <0.001 54.60 0.033 0.438
8 weeks 12 15 46.47 0.005 52.67 0.013 0.559 41.33 <0.001 47.93 0.008 0.568
12 weeks (crossover) 11 13 41.00 0.001 50.00 0.001 0.432 39.72 0.001 46.08 0.002 0.566
14 weeks 11 13 37.55 0.001 41.77 <0.001 0.734 37.45 0.001 39.62 <0.001 0.858
16 weeks 11 12 53.55 0.009 43.58 0.005 0.496 53.09 0.011 40.42 0.002 0.377
20 weeks 11 11 55.45 0.061 34.45 0.002 0.133 53.55 0.057 32.09 <0.001 0.113
24 weeks (opening) 10 10 82.10 0.930 9.30 <0.001 <0.001 80.80 1.000 10.00 <0.001 <0.001
32 weeks 10 8 34.10 0.004 20.88 0.001 0.413 32.33 0.003 20.88 0.001 0.468
40 weeks 9 8 12.22 <0.001 16.38 <0.001 0.627 11.44 <0.001 11.38 <0.001 0.992
48 weeks 9 8 9.00 <0.001 15.63 <0.001 0.491 8.78 <0.001 15.00 <0.001 0.515
*Group 1: treatment first (until week 12), then placebo (until week 24). Group 2: placebo first (until week 12), then treatment (until week 24). Both groups received treatment from week 25
through week 48.
†P-values for the difference between each visit and the baseline within the same group (paired t-test).
‡P-values for the difference between each group mean at the same visit (independent t-test).
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mean of 38.78 cm (95% CI: 34.84–42.72) and 36.38 cm
(95% CI: 32.94–39.81), respectively, which was statistically
different from the baseline mean (P0.008 and P<0.001,
respectively). No statistically significant differences were
observed between the groups at this phase (P0.971).
INTENTION TO TREAT ANALYSIS
The proportion of patients who reported more than 30%
reduction in pain on movement and handicap was com-
pared between treatment groups. The only statistically
significant difference between the groups was found at the
24th week. Ten of the 15 patients in the group which started
with placebo and finished with Zintona EC reported treat-
ment success for both parameters as defined above. Only
one patient in the other group reported treatment success
at the end of the second phase (P0.001).
When comparing the proportion of patients with more
than 5% reduction in target knee circumference, no statisti-
cally significant difference was observed between the
groups.
ADVERSE EVENTS
The only adverse effect was heartburn experienced by
two patients: one patient from group 1 who dropped out
after 1 week of treatment with Zintona EC and one from
group 2 who dropped out in week 48 while on Zintona EC.
INEFFICACY AND DROPOUT
In the first phase, three Zintona EC patients and two
placebo patients dropped out. In the second phase, three
Zintona patients and one placebo patient dropped out.
Altogether six Zintona patients and three placebo patients
dropped out before breaking the code. After code breaking,
three more patients dropped out of the study.
Discussion
Our data show that Zintona EC as used in the present
study was effective in reducing pain on movement, handi-
cap and knee circumference in patients with gonarthritis.
During the first 12 week phase of the study this effect
was not statistically different from that of placebo. However,
after crossover the difference between the group switched
from Zintona EC to placebo and the group switched from
placebo to Zintona EC became highly statistically signifi-
cant at 24 weeks in both VAS of pain on movement and of
handicap. The target knee circumference, though signifi-
cantly lower at 24 weeks in the group switched from
placebo to Zintona EC (as compared to baseline), was not
significantly different from the group switched from Zintona
EC to placebo. During the additional 24 week open study
the patients switched from placebo to Zintona EC again
showed statistically significant improvement (from base-
line) at week 48.
The fact that a statistically significant difference between
groups was reached only at week 24 could be explained as
follows: In the first phase, no significant difference was
observed because of the remarkable placebo effect of
different remedies used in OA10. In the second phase (after
crossover) the groups reached a statistically significant
difference only at week 24 because of a delayed effect of
Zintona EC and lack of a washout period. In the third phase
(after opening), when both groups received Zintona EC,
similar results were observed in both groups, as expected.
The higher dropout rate while on Zintona EC could be
related to possible side effects. In fact, two of the patients
(one in each phase) dropped out due to heartburn. It could
Fig. 3. Comparison of target knee circumference in the two treatment groups.
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be that the other patients who were lost to follow-up
suffered from heartburn or other side effects.
Routine laboratory evaluations, including blood counts,
liver tests and creatinine performed on day 0 and
weeks 4, 12, 16, 24, 32, 40 and 48, remained within normal
limits.
Our observations are in accord with those of Altman and
Marcussen6 and Bliddal et al.11 and support the need
for studies of longer duration than those previously pub-
lished6,11. In addition, data provided suggest lack of toxicity
of prolonged ginger extract therapy (48 weeks) as evalu-
ated by routine blood counts, liver and renal function tests.
However, a sound comparison between results of different
studies of ginger extracts is difficult because we do not
know the exact nature and dose of the active material in
this plant extract. Previous studies have attributed an
anti-prostaglandin and anti-inflammatory effect12,13 as
well as an anti-TNF effect14 to ginger preparations. The
reduction of target knee circumference observed in our
study may suggest an anti-inflammatory effect of Zintona
EC.
Our study has several limitations. The first is the absence
of a washout period at crossover. However, in the group
that started with placebo, a washout period is not needed,
since these patients did not receive any active medication
during the first phase. As for the second group, with the
absence of a washout period the effect of the drug (Zintona
EC) could continue after moving to placebo. This could
explain the fact that the patients in this group continued to
improve 2 weeks after starting on placebo and the onset of
deterioration was noticed only after 4 weeks (week 16 of
the study). We believe that this observation indicates a
positive effect of Zintona EC. Since two patients who were
on Zintona EC complained of heartburn one can speculate
that some after taste or other sensation would result in
unblinding. However, the patients who complained of heart-
burn were removed from the study and the researchers
remained blinded to the end of the controlled study at week
24. We believe that all other patients did not identify the
drug they received in each phase. Measuring of knee
circumference using a tape may not be valid. However,
since the investigators were blinded to the treatment
module, this measurement method could lead to a non-
differential bias. In that case, the size of the difference
between the study’s arms should be less than the real
difference. This could explain the nonsignificant difference
between the study groups observed for this parameter.
Finally, a higher dropout rate was observed in the patients
who were on Zintona EC, as compared to placebo. Six
Zintona EC patients and three placebo patients dropped
out before opening at week 24. Since we could not com-
pare means because the results concerning those who
were lost to follow-up were not available, we performed an
intention to treat analysis for success versus failure, refer-
ring to those lost to follow-up as treatment failures. This
assumption could lead to bias. If some of the patients who
were lost to follow-up in the placebo group had treatment
success, it could be that the difference between the groups
was smaller. On the other hand, if patients in the Zintona
EC group (in which most of the dropouts occurred) who
were lost to follow-up had treatment success, the difference
between groups could be larger.
Herbal medicinals are widely used in the United States
and elsewhere15,16. Ginger is considered one of the com-
monly used herbal medicinals17. It has been used for
vertigo18, motion sickness19 and as an antiemetic20. Evi-
dence is now provided suggesting that it may have a place
in the management of OA of the knee. Official recommen-
dations for the management of knee OA are periodically
revised3–5. Coated ginger extract may be considered for
this purpose in the future.
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